Form 4: Catalyst Pharmaceuticals Director Patrick McEnany Acquires Shares and Options

Patrick McEnany, a director at Catalyst Pharmaceuticals, acquired options and restricted stock units, increasing his holdings in the company.

Summary

• Patrick McEnany, a director and Chairman of the Board at Catalyst Pharmaceuticals, has reported acquiring 43,591 options to purchase common stock at an exercise price of $21.12.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• McEnany also acquired 5,327 restricted stock units, each representing a contingent right to receive one share of common stock upon vesting.
• Following these transactions, McEnany's direct holdings increased to 1,836,336 shares of common stock and 1,841,663 shares of common stock including the restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows a director increasing their stake in the company, which is generally seen as a good sign. However, it is a routine filing and not a major event.

Positives

• The acquisition of options and restricted stock units by a director signals confidence in the company's future performance.
• The vesting schedule of the options encourages long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who acquire or dispose of company securities. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• The vesting schedule of the options is typical for executive compensation packages in the pharmaceutical industry, aligning management's interests with long-term shareholder value.
• The acquisition of restricted stock units is also a common practice to incentivize performance and retention of key personnel.
• The reporting of these transactions is in line with SEC regulations for insider trading.

Stakeholder Impact

• The increased ownership by a director may be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Catalyst Pharmaceuticals, Patrick McEnany, stock options, restricted stock units, insider trading, share ownership, corporate governance